	drowsiness	20.801021836858965
	cyclobenzaprine selectivity	14.649271483086409
¡°	amitriptyline effectiveness	9.505046984356259
¡°	amitriptyline use	9.490485924363098
¡°	cyclobenzaprine research	8.146934884313568
¡°	amitriptyline muscle relaxant property	6.83953747050641
¡°	cyclobenzaprine propensity	6.2976495788949975
¡°	cyclobenzaprine side effect	6.111918190992338
¡°	prior art compound amitriptyline	5.69723252092663
	nervous system depressant	2.7187579006879887
	muscle spasm	1.9177835164494033
	skeletal muscle disorder	1.7605039105774625
	selective skeletal muscle relaxant	1.7174356971607196
	Sinha publication	0.8799099542336926
	Lance work	0.8762584121189182
	explanation	0.6143090922646549
	sale	0.6128703181465094
	argument	0.6125858294540499
	misrepresentation	0.6054722229773929
	NDA submission	0.5739097228457176
	FDA submission	0.5286676370849184
	acute painful musculoskeletal condition	0.44539767921681456
	adjunct	0.43838339361009204
	headache	0.40074983074944776
	credulity	0.40074983074944776
	defense	0.3775609067491615
	Parkinson disease	0.2732111439673116
	Investigational New Drug application	0.27072743870228855
	pharmacological resemblance	0.22808573434929225
	predominant side effect	0.19357531054108718
	Markey	0.16221747523864533
	potency	0.14186374340319566
	truly unexpected property	0.11630447252498886
	awareness	0.09374088656001119
	presume familiarity	0.08192242651406904
	frequent side effect	0.0669186470958616
	withholding material	0.06545683507438549
	procurement	0.06257970811808507
	FDA pto submission	0.056474784900106025
	chemical pharmacological clinical property	0.0492565835799436
	Delaware	0.042901745368691686
	Food Drug Administration FDA approval	0.03859186141688055
	package insert	0.03329819073246621
	early submission	0.02792674422409623
	abbreviate drug application	0.024938449707095158
	inequitable conduct	0.017876276678479856
	study	0.01392201576022623
	relief	0.011035374386895556
	New Drug Application	0.01052335048587736
	two compound	0.007352439400017715
	basic procedural fact	0.007193443654587637
	nonobviousness	0.0068628053369270935
	reasonable expectation	0.005592040368983186
	previously know compound	0.005051116505638334
	instant dispute	0.004641830671058629
	December	0.004376762620003456
	latter emphasis	0.004184990913424081
	District Court Opinion	0.003895179504191612
	comparison	0.0037999365587497104
	holder	0.0037441284706344288
	Obviousness	0.0036121010004846405
	July	0.003590238808622027
	May	0.002946128474211829
	several prior art publication	0.002879254337028689
	generic version	0.0021832843108642226
	datum	0.0020819126786821855
	PTO	0.0016273777894927576
	September	0.0013354119375427636
	test	0.0011585035185588326
	October	0.0009918538437884642
	four application	0.00029293078180179887
	method	0.00018764095410172507
	certain type	0.00011976089800809934
	clear convincing evidence	9.977436207629477e-05
	Trademark Office	9.639421183757016e-05
	view	6.361698010178032e-05
	prior art disclosure	4.998374079936331e-05
	trial	6.254737926561529e-06
	part	5.61889268779282e-06
	purpose	5.370149397009946e-06
	light	3.2472440458745683e-06
	prior art reference	2.762533487472546e-07
	infringement action	1.9148983415415744e-07
	issue	1.7859599746675e-09
	Co.	5.276693250574788e-10
	Appeals	0.0
	court	0.0
